Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.

Immune responders as defined by expansion of antigen‐specific T cells against WT1 or PRAME showed a trend towards better OS (median not yet reached vs. 976 days; Figure 5 e) and RFS (median not yet reached vs. 509 days; Figure 5 f) than immune non‐responders, but statistical significance was not reached because of the low patient number.

also in 53,322 other papers